Adverse events (self‐harm) Assessed by: mean number of self‐harm days in past 2 months Timing of assessment: 2 months · adults with antisocial personality disorder
1 finding from 1 review
Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.72 [0.45, 1.14]
Studies not reported
Low
Intervention not reported
Serious adverse events Measured by: proportion of any serious adverse events Average study duration (range): 4.7 months (14 days to 21 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Non‐serious adverse events Measured by: proportion of any non‐serious adverse events Average study duration (range): 5.99 months (1 day to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Adverse events (hospital records/every 6 weeks) · asymptomatic carotid stenosis
Lipid‐lowering agent showed no clear difference in adverse events (only reported for two studies: one study used CT… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to adverse events of unknown severity Measured by: proportion of participants withdrawn from treatment Average study duration (range): 4.6 months (21 days to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Adverse events (number of events) ( · children aged from 29 days to 12 years with pneumonia
Chest physiotherapy showed no clear difference in adverse events (number of events) ( compared with no chest physiotherapy (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)
It is very uncertain whether the intervention changes serious adverse eventsClinical manifestation and laboratory… (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)
The intervention showed no clear difference in non‐serious adverse eventsClinical manifestation and laboratory… (low certainty).
1 finding from 1 review
Number of participants with any adverse events№ of participants: 10(1 RCT) · idiopathic hypersomnia
Clarithromycin showed no clear difference in number of participants with any adverse events№ of participants:… compared with placebo (low certainty).
1 finding from 1 review
OR 0.41 [0.01, 12.64]
Studies not reported
Low
Number of participants with any adverse events№ of participants: 102(2 RCTs) · idiopathic hypersomnia
Modafinil showed no clear difference in number of participants with any adverse events№ of participants:… compared with placebo (low certainty).
1 finding from 1 review
OR 1.68 [0.28, 9.94]
Studies not reported
Low